We have a robust and sustainable pipeline with 3 clinical stage assets (EMB-01, EMB-06 and EMB-07) and more than 10 preclinical stage candidates. Our proprietary FIT-Ig® platform and other technical capabilities enable us to target three strategic oncology areas (tumor targeting, dual checkpoint regulators, immune cell engagers) and maintain our strong momentum to advance additional preclinical assets to the clinic.
Program
Target
Indication
Mono/
Combo
Combo
Rights
PCC
IND-
Enabling
Enabling
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
Upcoming Milestone
Oncology
EMB-01 EGFR/cMET
GI Cancers (CRC. HCC. gastric, Cholangiocarcinoma)
Mono
Global
Expected Phase Ib/ll trial completion in H2 2025
CRC
Mono
Global
Expected Phase ll initiation in H2 2025
CRC
+Chemo
Global
Expected Phase I initiation pending interim data readout of Phase ll mono
EMB-07 ROR1/CD3
Hematologie malignaneies / Solid tumors
Mono
Global
Expected Phase I trial completion in early 2026
Hematologic malignancies
Combo
Global
Expected IND submission in H2 2025
EMB-06 BCMA/CD3
Multiple myeloma
Mono
China
Upcoming development pending agreement with Candid
EM1032
ALPP(G)/CD3
Solid tumors
TBD
Global
Expected IND submission in H1 2026
EM1034
LY6G6D/CD3
Solid tumors
TBD
Global
Expected IND submission in 2026
EM1031
KLK2/CD3
Prostate cancer
TBD
N/A
N/A
Immunology
EMB-06 BCMA/CD3
Autoimmune diseases (Autoantibody diseases)
Mono
China
Upcoming development pending agreement with Candid
EM1039
Undisclosed trispecific TCE
Autoimmune diseases (B cell related)
TBD
Global
Expected IND enabling studies by early 2026
EM1042
Undiselosed TCE
Autoimmune diseases (Inflammatory cell related)
TBD
Global
Expected IND enabling studies in 2026
Non-TCE Programs
Core Product
Key Product
Non-TCE Programs
Core Product
Key Product
